



長期照護藥師培訓教案

常見精神科及神經內科疾病處方 判讀及處置

高雄榮民總醫院 藥劑部
陳淑梅 藥師



藥事照護

發現了
什麼藥物
相關問題

如何解決
問題

預防了
什麼藥物或疾
病相關問題

要追蹤
什麼





巴金森氏病





常見老人運動障礙疾病



Movement disorder

■ Hypokinetic disorder

運動減退

- Parkinson's disease
- Secondary parkinsonism
- Progressive supranuclear palsy (PSP)
進行性核上眼神經麻痺症
- Multisystem atrophy (MSA) 多發性系統退化症

■ Hyperkinetic disorder

運動機能亢進

- Tremor (eg, essential tremor, dystonic tremor 肌張力異常性顫抖, drug-induced tremor, physiological)
- Tic disorder 抽動性疾患 (eg, tourette's syndrome (TS))
- Chorea 舞蹈症 (eg, huntington's disease) 亨丁頓舞蹈症
- Myoclonus 肌躍症
- Dystonia 肌張力不全
- Ataxia 運動失調症



Tremors





Clinical Classification of Tremors

- Enhanced physiologic tremors
- Essential tremor
- Tremors as part of specific neurologic diseases





Physiologic tremors





Clinical Classification of Tremors

- physiologic tremors

- Enhanced physiologic tremors
 - Metabolic causes
 - Toxic causes
 - Drug and alcohol withdrawal states



Clinical Classification of Tremors - physiologic tremors

Causes of Enhanced Physiologic Tremor

- Related to drugs and alcohol
 - Alcohol withdrawal
 - Beta adrenergic drugs (Terbutaline)
 - Valproate
 - Lithium
 - Methylxanthines (caffeine theophylline)
 - Tricyclic antidepressants
 - Hormonal drugs (thyroid supplements and adrenocorticosteroids)
 - Metrizamide used as contrast agent
 - Amiodarone
 - Cyclosporine





Essential tremor





Clinical Classification of Tremors

- Essential Tremor

- Essential tremor (ET) is the most common neurologic cause of postural or action tremor, with an estimated prevalence worldwide of up to **5 percent of the population**.
- The incidence of ET **increases with age**, although it often affects young individuals, especially when it is familial.





Clinical Classification of Tremors

- Essential Tremor

- A community-based study from Canada showed
 - prevalence of 14% for essential tremor (ET) in persons over the age of 65 years compared with a rate of 3% for Parkinson's disease.
- The etiology of ET is unknown.
- Brain imaging and pathologic studies are normal, but positron emission tomography (PET) studies reveal hypermetabolism in the cerebellum, red nuclei, and thalamic and inferior olivary nuclei.





Clinical Classification of Tremors

- Essential Tremor

- The diagnosis of ET is clinical, and neuroimaging is not indicated.
- ET as a risk factor for Parkinson's disease remains unproven although they often coexist.
- Over 25 randomized, placebo-controlled studies have established **propranolol** as the most effective treatment to decrease the amplitude of the tremor of the hands and tongue in about 50% to 60% of the patients.





Criteria for diagnosis of essential tremor

Core criteria

Bilateral action tremor of the hands and forearms (**but not rest tremor**)

Absence of other neurologic signs, with the exception of cogwheel phenomenon

May have isolated **head tremor** with no signs of dystonia

Secondary criteria

Long duration (>3 years)

Positive **family history**

Beneficial response to **alcohol**

Criteria for the diagnosis of essential tremor. Neurology 2000; 54(suppl 4):s7





Symptoms or signs suggestive of tremor other than essential tremor

Symptom or sign	Likely differential diagnosis
Unilateral tremor, leg tremor, rigidity, bradykinesia, rest tremor	Parkinson disease
Gait disturbance	Parkinson disease, cerebellar tremor
Focal tremor	Dystonic tremor
Isolated head tremor with abnormal posture (head tilt or turning)	Dystonic tremor
Sudden or rapid onset	Psychogenic tremor, toxic tremor
Current drug treatment that may cause or exacerbate tremor	Drug-induced or toxic tremor





Clinical Classification of Tremors - Treatments for Essential Tremor

■ Beta-adrenergic blocking drugs

- Propranolol
- Metoprolol
- Nadolol

需藥？

■ Primidone

■ Clonazepam

■ Botulinum toxin injection 肉毒桿菌毒素

■ Stereotactic thalamic stimulation

實體定位丘腦的刺激



Specific neurologic diseases



Clinical Classification of Tremors

- Tremors as part of specific neurologic diseases

- Parkinson's disease
- Cerebellar disease (multiple sclerosis)
- Wilson's disease
- Rare cases of peripheral neuropathy





Parkinson's disease

Diagnosis of Parkinson disease-UpToDate®

Pharmacologic treatment of Parkinson disease-UpToDate®

Nonpharmacologic management of Parkinson disease-UpToDate®





Demographics

Age

- Parkinson's disease is estimated to affect 1% of individuals >55 years of age in the US
- Peak age at onset is between 55 and 65 years. **The prevalence increases with age.**
- 5% of cases occur between 21 and 39 years of age
- Rare cases of juvenile Parkinson's disease are reported

Geography

- Except for living in rural conditions with exposure to well water and pesticides, no geographic vulnerability exists
- Parkinson's disease occurs throughout the world.



Demographics

Genetics

- Although Parkinson's disease is generally considered to be a sporadic disease, autosomal dominant and autosomal recessive inheritance have been documented
- **Familial parkinsonism** is estimated to be responsible for **5-10%** of Parkinson's disease cases
- Vulnerability to **environmental** influences that may cause the disease may be genetically determined. Monozygotic twin studies support this concept.



Clinical features of Parkinson's disease

The first signs of PD are usually :

- a subtle fatigue
- discomfort or shakiness
- memory lapses, slower thinking
- depression become common
- Patients may develop a 'masked' or expressionless face

Finally, the four primary symptoms appear




Clinical features of Parkinson's disease -Cardinal features

- **Tremor at rest:** Shaking or trembling begins in the hand, arm, leg, face, and it spreads, sometimes affecting only one side of the body.
 - Tremors worsen when the muscles are relaxed or when the individual is stressed
 - Tremor disappears during sleep or when the muscles are intentionally moved
- **Rigidity or hypertonia:** permanent contraction of muscles
- **Akinesia or Bradykinesia:** Spontaneous and automatic movement are lost and all movement becomes extremely slow.
- **Postural instability:** Balance and coordination become impaired. Patients tend to lean forward or backward, and to develop a stooped posture. Walking with quick and small steps



What causes Parkinson's disease ?


- PD is caused by a loss of neurons in a part of the brain called the substantia nigra





- 巴金森病的主要病變是在腦部的**黑質及紋狀體**。黑質為製造並貯存紋狀體所需要的神經遞質—多巴胺的場所，並經**黑質—紋狀體環路**向紋狀體輸送**多巴胺**。
- 多巴胺為紋狀體的**抑制性神經遞質**，乙醯膽鹼為紋狀體的**興奮性神經遞質**。
- 在正常人，這兩種神經遞質處在一種動態平衡狀態。
- 巴金森病患者的黑質細胞大量劣變而消失，多巴胺的製造減少，而乙醯膽鹼的作用相對亢進，所以，產生臨床上的諸多症狀。

由於Dopamine不能透過血腦屏障，因此，不能直接口服或注射多巴胺來治療，但可以口服易於透過血腦屏障的L-dopa來治療。L-dopa在腦內經過脫羧的作用，轉化為Dopamine，從而起到補充Dopamine的作用，以達到臨床治療巴金森病的目的



COMT=cathechol O-methyltransferase DDC= dopa decarboxylase

DOPAC=dihydroxyphenylacetic acid

HVA=homovanillic acid MAO=monoamine oxidase 3-OMD=3-O-methyl dopa

Disorders that can **mimic** Parkinson disease

Neurodegenerative causes

Alzheimer disease

Corticobasal degeneration

Dementia with Lewy bodies

Frontotemporal dementia

Huntington's disease

Multiple system atrophy

Parkinsonism-dementia-ALS complex of Guam

Progressive supranuclear palsy

Spinocerebellar ataxias

Disorders that can **mimic** Parkinson disease

Symptomatic

Drug-induced (neuroleptics, other dopamine receptor antagonists)

Infectious (post-encephalitic, Creutzfeldt-Jakob disease)

Metabolic (Wilson's disease, neurodegeneration with brain iron accumulation, hepatocerebral degeneration, parathyroid disorders)

Neoplastic

Post-traumatic

Toxic (carbon monoxide, manganese, MPTP)

Vascular

Other

Essential tremor

Normal pressure hydrocephalus

Causes of iatrogenic parkinsonism

Agent	Examples
Classic antipsychotic agents	Chlorpromazine (Thorazine), fluphenazine (Prolixen), haloperidol (Haldol), perphenazine (Trilafon), thioridazine (Mellaril), thiothixene (Navane), trifluoperazine
Atypical antipsychotic agents	Clozapine (Clozaril), risperidone (Risperdal), olanzapine (Zyprexa), aripiprazole (Abilify), quetiapine (Seroquel) ziprasidone (Geodon)
Antiemetics, motility agents	Prochlorperazine (Compazine), promethazine (Phenergan), metoclopramide (Reglan)
Chemotherapeutic agents	Fluorouracil (5-FU), vincristine, doxorubicin (Adriamycin)
Calcium channel blockers	Cinnarizine, Flunarizine
Others	Amiodarone, bethanechol, fentanyl, droperidol, lithium, meperidine (Demerol), pyridostigmine, reserpine, divalproex sodium (Depakote)